GN-NORFLOXACIN norfloxacin 400mg tablet blister pack Australia - engelsk - Department of Health (Therapeutic Goods Administration)

gn-norfloxacin norfloxacin 400mg tablet blister pack

strides pharma science pty ltd - norfloxacin, quantity: 400 mg - tablet, film coated - excipient ingredients: calcium hydrogen phosphate dihydrate; sodium starch glycollate; colloidal anhydrous silica; magnesium stearate; purified talc; titanium dioxide; hypromellose; macrogol 400 - indications: the treatment of adults with complicated and uncomplicated urinary tract infections that are caused by susceptible strains of microorganisms. the treatment of adults with gastrointestional infections, in particular shigellosis and traveller's diarrhoea. note: specimens for culture and susceptibility testing should be obtained prior to and during treatment if clinical response warrants. suppression in adults of chronic, recurrent urinary tract infections.

GN-INDAPAMIDE indapamide hemihydrate 2.5mg sugar coated tablet bottle Australia - engelsk - Department of Health (Therapeutic Goods Administration)

gn-indapamide indapamide hemihydrate 2.5mg sugar coated tablet bottle

strides pharma science pty ltd - indapamide hemihydrate, quantity: 2.5 mg - tablet, sugar coated - excipient ingredients: lactose monohydrate; maize starch; magnesium stearate; povidone; purified talc; calcium carbonate; titanium dioxide; sucrose; acacia; ethyl acetate; purified water; stearic acid; industrial methylated spirit; polyvinyl acetate phthalate; shellac; white beeswax; carnauba wax - management of essential hypertension. it may be tried as the sole therapeutic agent in the treatment of mild to moderate hypertension. normally indapamide is used as the initial agent in multiple drug regimens.

GN-INDAPAMIDE indapamide hemihydrate 2.5mg sugar coated tablet blister pack Australia - engelsk - Department of Health (Therapeutic Goods Administration)

gn-indapamide indapamide hemihydrate 2.5mg sugar coated tablet blister pack

strides pharma science pty ltd - indapamide hemihydrate, quantity: 2.5 mg - tablet, sugar coated - excipient ingredients: lactose monohydrate; maize starch; magnesium stearate; povidone; purified talc; calcium carbonate; titanium dioxide; sucrose; acacia; ethyl acetate; purified water; stearic acid; industrial methylated spirit; polyvinyl acetate phthalate; shellac; white beeswax; carnauba wax - management of essential hypertension. it may be tried as the sole therapeutic agent in the treatment of mild to moderate hypertension. normally indapamide is used as the initial agent in multiple drug regimens.

GN-OXALIPLATIN oxaliplatin100 mg powder for injection vial Australia - engelsk - Department of Health (Therapeutic Goods Administration)

gn-oxaliplatin oxaliplatin100 mg powder for injection vial

alphapharm pty ltd - oxaliplatin, quantity: 100 mg - injection, powder for - excipient ingredients: lactose monohydrate - oxaliplatin is indicated for adjuvant treatment of stage iii (duke's c) colon cancer, in combination with a fluoropyrimidine agent,oxaliplatin in combination with fluorouracil and folinic acid is indicated for the treatment of advanced colorectal cancer,oxaliplatin in combination with capecitabine, with or without bevacizumab, is indicated for the treatment of patients with metastatic colorectal cancer,oxaliplatin in combination with epirubicin and either capecitabine or fluorouracil, is indicated for the treatment of patients with advanced oesophagogastric cancer

GN-OXALIPLATIN oxaliplatin 50 mg powder for injection vial Australia - engelsk - Department of Health (Therapeutic Goods Administration)

gn-oxaliplatin oxaliplatin 50 mg powder for injection vial

alphapharm pty ltd - oxaliplatin, quantity: 50 mg - injection, powder for - excipient ingredients: lactose monohydrate - oxaliplatin is indicated for adjuvant treatment of stage iii (duke's c) colon cancer, in combination with a fluoropyrimidine agent,oxaliplatin in combination with fluorouracil and folinic acid is indicated for the treatment of advanced colorectal cancer,oxaliplatin in combination with capecitabine, with or without bevacizumab, is indicated for the treatment of patients with metastatic colorectal cancer,oxaliplatin in combination with epirubicin and either capecitabine or fluorouracil, is indicated for the treatment of patients with advanced oesophagogastric cancer